Recommended Topic Related To:

Uceris

"The U.S. Food and Drug Administration today approved a new use for Simponi (golimumab) injection to treat adults with moderate to severe ulcerative colitis.

Simponi works by blocking tumor necrosis factor (TNF), which plays an important"...

Uceris

Uceris Side Effects Center

Medical Editor: John P. Cunha, DO, FACOEP

Uceris (budesonide) extended release is a corticosteroid used to induce remission of active, mild to moderate ulcerative colitis. Common side effects include headache, nausea, abdominal pain, fatigue, flatulence, bloating, acne, urinary tract infection, joint pain, and constipation.

The recommended dosage of Uceris for the induction of remission in adult patients with active, mild to moderate ulcerative colitis is 9 mg taken orally once daily in the morning with or without food for up to 8 weeks. Uceris may interact with ketoconazole or grapefruit juice. Tell your doctor all medications and supplements you use. During pregnancy, Uceris should be used only if prescribed. This drug passes into breast milk. Because of the potential for serious adverse reactions in nursing infants from Uceris, consult your doctor before breastfeeding.

Our Uceris (budesonide) extended release tablets Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

What is Prescribing information?

The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.

Uceris FDA Prescribing Information: Side Effects
(Adverse Reactions)

SIDE EFFECTS

Systemic glucocorticosteroid use may result in the following:

  • Hypercorticism and Adrenal Suppression [See WARNINGS AND PRECAUTIONS]
  • Symptoms of steroid withdrawal in those patients transferring from Systemic Glucocorticosteroid Therapy [See WARNINGS AND PRECAUTIONS]
  • Immunosuppression [See WARNINGS AND PRECAUTIONS]
  • Increased Systemic Glucocorticosteroid Susceptibility [See WARNINGS AND PRECAUTIONS]
  • Other Glucocorticosteroid Effects [See WARNINGS AND PRECAUTIONS]

Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The safety of UCERIS has been evaluated in controlled and open-label clinical trials which enrolled a combined total of 1105 patients with ulcerative colitis.

In two 8-week, placebo-controlled studies in patients with active disease (Study 1 and Study 2), a total of 255 patients received UCERIS 9 mg, 254 patients received UCERIS 6 mg, and 258 patients received placebo. They ranged in age from 18-77 years (mean 43), 56% were male, and 75% were Caucasian. The most common adverse reactions were headache, nausea, decreased blood cortisol, upper abdominal pain, fatigue, flatulence, abdominal distension, acne, urinary tract infection, arthralgia, and constipation. The adverse reactions occurring in 2% or more of patients on therapy with UCERIS 9 mg are summarized in Table 1.

Table 1: Summary of Adverse Reactions in Two Placebo Controlled Trials Experienced by at Least 2% of the UCERIS 9 mg Group (Studies 1 and 2)

  UCERIS 9 mg
(N = 255)
n (%)
UCERIS 6 mg
(N = 254)
n (%)
Placebo
(N = 258)
n (%)
Headache 29 (11.4) 37 (14.6) 27 (10.5)
Nausea 13 (5.1) 12 (4.7) 11 (4.3)
Decreased Blood Cortisol 11 (4.3) 6 (2.4) 1 (0.4)
Upper Abdominal Pain 10 (3.9) 8 (3.1) 5 (1.9)
Fatigue 8 (3.1) 5 (2.0) 5 (1.9)
Flatulence 6 (2.4) 8 (3.1) 5 (1.9)
Abdominal Distension 6 (2.4) 4 (1.6) 2 (0.8)
Acne 6 (2.4) 2 (0.8) 5 (1.9)
Urinary Tract Infection 5 (2.0) 1 (0.4) 1 (0.4)
Arthralgia 5 (2.0) 5 (2.0) 4 (1.6)
Constipation 5 (2.0) 1 (0.4) 2 (0.8)

Of UCERIS 9 mg patients, a total of 15% discontinued treatment due to any adverse event (including adverse reactions) compared with 17% in the placebo group.

Table 2 summarizes the percentages of patients reporting glucocorticoid related effects in the 2 placebo-controlled studies.

Table 2: Summary of Glucocorticoid Related Effects in Two Placebo-Controlled Trials (Studies 1 and 2)

  UCERIS 9 mg
(N = 255)
n (%)
UCERIS 6 mg
(N = 254)
n (%)
Placebo
(N = 258)
n (%)
Overall 26 (10.2) 19 (7.5) 27 (10.5)
  Mood changes 9 (3.5) 10 (3.9) 11 (4.3)
  Sleep changes 7 (2.7) 10 (3.9) 12 (4.7)
  Insomnia 6 (2.4) 6 (2.4) 8 (3.1)
  Acne 6 (2.4) 2 (0.8) 5 (1.9)
  Moon face 3 (1.2) 3 (1.2) 4 (1.6)
  Fluid retention 2 (0.8) 3 (1.2) 3 (1.2)
  Hirsutism 1 (0.4) 0 0
  Striae rubrae 0 0 2 (0.8)
  Flushing 0 1 (0.4) 3 (1.2)

No clinically significant differences were observed with respect to the overall percentages of patients with any glucocorticoid related effects between UCERIS and placebo after 8 weeks of induction therapy.

Study 3 was an open-label study evaluating UCERIS 9 mg once daily for 8 weeks in 60 patients who had previously completed an 8-week induction study (Study 1), but had not achieved remission. Among patients who took UCERIS 9 mg up to 16 weeks cumulatively across Study 1 and Study 3 combined, similar rates of adverse reactions and glucocorticoid-related effects were seen compared to those who took UCERIS 9 mg for 8 weeks in Study 1.

In Study 4, the safety of long-term treatment with UCERIS 6 mg was evaluated in a placebo-controlled 12-month maintenance study of 123 patients. Patients who had previously completed 8 weeks of therapy in any induction study (Study 1, 2, or 3) and were in remission were randomized to UCERIS 6 mg or placebo once daily for 12 months. In patients who took UCERIS 6 mg for up to 12 months, similar rates of adverse reactions were seen between placebo and UCERIS 6 mg. After up to 12 months of study treatment, 77% (27/35) of the patients in the UCERIS 6 mg and 74% (29/39) of the patients in the placebo treatment groups had normal bone density scans.

In Study 4, the glucocorticoid related effects were similar in patients with up to 12 months of therapy with UCERIS 6 mg and placebo. (Table 3)

Table 3: Summary of Glucocorticoid Related Effects Over 12-month Treatment (Study 4)

  UCERIS 6 mg
(N = 62)
n (%)
Placebo
(N = 61)
n (%)
Overall 9 (14.5) 7 (11.5)
Insomnia 4 (6.5) 4 (6.6)
Mood changes 4 (6.5) 2 (3.3)
Moon face 3 (4.8) 3 (4.9)
Sleep changes 3 (4.8) 3 (4.9)
Acne 3 (4.8) 0
Hirsutism 3 (4.8) 0
Flushing 1 (1.6) 1 (1.6)
Fluid retention 1 (1.6) 1 (1.6)

Postmarketing Experience

The following adverse reactions have been identified during postapproval use of oral budesonide. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Immune System Disorders:anaphylactic reactions

Nervous System Disorders:benign intracranial hypertension

Psychiatric Disorders:mood swings

Read the entire FDA prescribing information for Uceris (Budesonide Extended-Release Tablets) »

A A A

Report Problems to the Food and Drug Administration

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


Women's Health

Find out what women really need.


NIH talks about Ebola on WebMD